WallStreetZenWallStreetZen

NASDAQ: AZN
Astrazeneca PLC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their AZN stock forecasts and price targets.

Forecast return on equity

Is AZN forecast to generate an efficient return?

Company
45.54%
Industry
-2,104.03%
Market
146.96%
AZN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is AZN forecast to generate an efficient return on assets?

Company
18.12%
Industry
23.17%
AZN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

AZN earnings per share forecast

What is AZN's earnings per share in the next 3 years based on estimates from 30 analysts?

Avg 1 year Forecast
$9.34+249.1%
Avg 2 year Forecast
$10.60+296.24%
Avg 3 year Forecast
$11.77+339.87%
AZN's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

AZN revenue forecast

What is AZN's revenue in the next 3 years based on estimates from 27 analysts?

Avg 1 year Forecast
$59.9B+6.06%
Avg 2 year Forecast
$63.5B+12.41%
Avg 3 year Forecast
$67.2B+18.85%
AZN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

AZN earnings growth forecast

How is AZN forecast to perform vs Drug Manufacturers - General companies and vs the US market?

Company
63.93%
Industry
34.85%
Market
41.33%
AZN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
AZN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
AZN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

AZN revenue growth forecast

How is AZN forecast to perform vs Drug Manufacturers - General companies and vs the US market?

Company
5.92%
Industry
6.83%
Market
25.15%
AZN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
AZN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

AZN vs General Drug Manufacturer Stocks

TickerPricePrice TargetUp/downsideConsensus
AZN$83.29N/AN/A
NVS$130.36$118.00-9.48%Strong Sell
MRK$87.49$93.25+6.58%Hold
AMGN$291.76$307.44+5.38%Hold
GILD$120.94$124.00+2.53%Strong Buy
View Top General Drug Manufacturer Stocks

Astrazeneca Stock Forecast FAQ

What is AZN's earnings growth forecast for 2025-2027?

(NASDAQ: AZN) Astrazeneca's forecast annual earnings growth rate of 63.93% is forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 34.85%, and it is also forecast to beat the US market's average forecast earnings growth rate of 41.33%.

Astrazeneca's earnings in 2025 is $8,295,000,000.On average, 30 Wall Street analysts forecast AZN's earnings for 2025 to be $14,474,365,000, with the lowest AZN earnings forecast at $12,123,170,000, and the highest AZN earnings forecast at $15,265,950,000. On average, 30 Wall Street analysts forecast AZN's earnings for 2026 to be $16,428,915,000, with the lowest AZN earnings forecast at $14,381,830,000, and the highest AZN earnings forecast at $18,595,815,000.

In 2027, AZN is forecast to generate $18,238,230,000 in earnings, with the lowest earnings forecast at $15,645,700,000 and the highest earnings forecast at $21,710,850,000.

If you're new to stock investing, here's how to buy Astrazeneca stock.

What is AZN's revenue growth forecast for 2025-2027?

(NASDAQ: AZN) Astrazeneca's forecast annual revenue growth rate of 5.92% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.83%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.15%.

Astrazeneca's revenue in 2025 is $56,501,000,000.On average, 27 Wall Street analysts forecast AZN's revenue for 2025 to be $92,883,750,000,000, with the lowest AZN revenue forecast at $83,554,300,000,000, and the highest AZN revenue forecast at $96,175,950,000,000. On average, 27 Wall Street analysts forecast AZN's revenue for 2026 to be $98,446,700,000,000, with the lowest AZN revenue forecast at $87,472,700,000,000, and the highest AZN revenue forecast at $105,728,600,000,000.

In 2027, AZN is forecast to generate $104,084,050,000,000 in revenue, with the lowest revenue forecast at $91,786,350,000,000 and the highest revenue forecast at $116,713,450,000,000.

What is AZN's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: AZN) forecast ROA is 18.12%, which is lower than the forecast US Drug Manufacturers - General industry average of 23.17%.

What is AZN's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: AZN) Astrazeneca's current Earnings Per Share (EPS) is $2.68. On average, analysts forecast that AZN's EPS will be $9.34 for 2025, with the lowest EPS forecast at $7.82, and the highest EPS forecast at $9.85. On average, analysts forecast that AZN's EPS will be $10.60 for 2026, with the lowest EPS forecast at $9.28, and the highest EPS forecast at $12.00. In 2027, AZN's EPS is forecast to hit $11.77 (min: $10.09, max: $14.01).

What is AZN's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: AZN) forecast ROE is 45.54%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.